https://european-biotechnology.net/wp-content/uploads/2025/07/Gourmey2-1030x548-1.jpg
548
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-07-10 18:06:482025-07-10 18:06:48UK Food Standards Agency accepts Gourmey’s application for cultivated Foie Gras
https://european-biotechnology.net/wp-content/uploads/2025/07/RheticusEvonik-e1752130242507-1030x579-1.jpg
579
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-07-10 11:44:112025-07-10 11:44:11First step towards scaling chemical production from CO₂
https://european-biotechnology.net/wp-content/uploads/2025/07/IMG_0324.jpg
540
960
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-07-10 09:00:452025-07-10 12:02:03Nuclidium fuels next radiopharma wave
https://european-biotechnology.net/wp-content/uploads/2025/07/Platform-page-Covalent-retention-web-1030x538-1.jpeg
538
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-07-09 07:00:302025-07-09 07:00:30Actithera: Radiopharma Funding Gathers Huge Momentum
https://european-biotechnology.net/wp-content/uploads/2025/07/Exosome-Schmuckbild-e1752043172924.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-07-09 06:41:522025-07-09 06:41:52Ciloa SAS secures €6.5m to advance lead candidate APN-sEV into clinical development
https://european-biotechnology.net/wp-content/uploads/2025/07/Solarfoods2-e1751963179861-1030x579-1.jpg
579
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-07-08 08:29:152025-07-08 08:29:15Solar Foods continues expansion in the US
https://european-biotechnology.net/wp-content/uploads/2025/07/EC-Life-Sciences-Strategy-e1751894302405.jpg
360
639
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-07-07 13:41:172025-07-07 13:41:17European Commission to fund Life Sciences Strategy using Cohesion Fund resources
https://european-biotechnology.net/wp-content/uploads/2025/07/Sandoz-Brnik-1-e1751523358685.jpg
428
760
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-07-03 09:23:182025-07-03 09:23:18Sandoz breaks ground on US$440m biosimilar facility in Slovenia
https://european-biotechnology.net/wp-content/uploads/2025/07/Macro_Illos_05-1.jpg
288
560
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-07-02 05:31:172025-07-02 22:02:02Argenx and Unnatural Products ink US$1.5bn macrocycle deal
https://european-biotechnology.net/wp-content/uploads/2025/07/Vetter-e1751364099507.jpg
304
540
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-07-01 13:39:202025-07-01 13:39:20Vetter invests US$285m in Chicago production facility
Scroll to top
